Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

Gill, Beant S.; Vargo, John A.; Balasubramani, Goundappa K.; Beriwal, Sushil

doi:10.1016/j.ijrobp.2015.07.2265

Cited by 10 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a more recent and larger retrospective study that included 2,539 patients with stages I to II MCL, estimated 3-year OS for patients receiving chemotherapy, RT, or chemotherapy plus RT were 67.8, 72.4, and 79.8%, respectively, which was statistically significant, and appeared to support the idea that combined therapy may improve survival. 77 Extrapolating these data from patients with early-stage nodal MCL to patients with primary colorectal MCL, we again confront the issue of both short-and long-term toxicities of bowel irradiation. If limited-stage disease involves an area of the colon that cannot be safely irradiated, we suggest upfront surgical resection, with adjuvant RT plus or minus chemoimmunotherapy, depending on surgical margins (►Fig.…”

Section: Colorectal Mantle Lymphomamentioning

confidence: 99%

Colorectal Lymphoma: A Review

Chen

Okada

2018

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) that primarily involves the colon is rare and should be distinguished from the more common systemic nodal lymphoma. It has unique clinical expectations and management consideration. Different histologic subtypes of NHL involve the colon, which varies in the clinical behavior and likelihood of obtaining durable remissions with treatment. This article will review the current understanding of the different histologic subtypes of primary colorectal lymphoma and propose management algorithms.

show abstract

Section: Colorectal Mantle Lymphomamentioning

confidence: 99%

Colorectal Lymphoma: A Review

Chen

Okada

2018

Clinics in Colon and Rectal Surgery

View full text Add to dashboard Cite

show abstract

“…In a multicenter analysis of early stage MCL predominately in the head and neck by Dabaja et al, 4 they did not find any difference in OS among different treatment groups, categorized as chemotherapy, chemo-radiation, radiation, or observation. Gill et al 10 found improved OS with CRT compared to monotherapy in an analysis of early stage MCL using the National Cancer Database.…”

Section: Discussionmentioning

confidence: 99%

Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival

Breen

Chao

Mehra

et al. 2021

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objectives: To describe disease characteristics and treatment and to analyze survival and mortality for extranodal mantle cell lymphoma (MCL) of the head and neck. Methods: Patients with extranodal MCL—excluding primary sites in the salivary glands, eye, and adnexa—were identified from the Surveillance, Epidemiology, and End Results (SEER) 18 Registries (2000-2015). Overall survival (OS) and cumulative incidence of MCL and non-MCL mortality were calculated. Factors associated with MCL and non-MCL mortality were analyzed with cause-specific hazard models. Results: Five hundred nine patients met criteria for descriptive analysis and 294 patients met criteria for survival analysis, with a median follow-up of 58 months. The most common sites for MCL were the oropharynx (66.0%), nasopharynx (19.1%), and oral cavity (8.4%). The most common treatment received was chemotherapy alone (48.9%), followed by chemoradiation therapy (16.9%), and radiation therapy alone (10.4%). The proportion of cases diagnosed as early-stage disease ranged from 31% of sinonasal MCLs to 83% of laryngeal MCLs. At 5 years, OS was 63% (95% CI: 57%-69%). There was no significant difference in OS ( P = .79), cumulative incidence of MCL mortality ( P = .76), or cumulative incidence of non-MCL mortality ( P = .98) by anatomic site. Comparing early-stage to late-stage disease, there was no significant difference in OS ( P = .38), cumulative incidence of MCL mortality ( P = .07), or cumulative incidence of non-MCL mortality ( P = .14). Multivariate analysis showed increased hazard of MCL mortality for patients that were older or that presented with stage III or stage IV disease. Conclusion: The oropharynx is the most common subsite of head and neck MCLs, followed by the nasopharynx. Primary head and neck MCLs appear to present at an earlier stage than MCLs of other regions. In particular, laryngeal and hypopharyngeal MCLs may present as stage I or II disease.

show abstract

Radiation Therapy in the Management of Mantle Cell Lymphoma

Milgrom

2016

Radiation Therapy in Hematologic Malignancies

View full text Add to dashboard Cite

Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

Cited by 10 publications

References 29 publications

Colorectal Lymphoma: A Review

Colorectal Lymphoma: A Review

Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival

Radiation Therapy in the Management of Mantle Cell Lymphoma

Contact Info

Product

Resources

About